Pancreatic cancer
Conditions
Interventions
Stereotactic radiotherapy
Sponsors
Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Borderline resectable or unresectable pancreatic cancer (with or without prior chemotherapy, with or without regional lymph node metastasis) (2) Histologically or cytologically proven adenocarcinoma (3) No obvious invasion to gastrointestinal organs such as stomach and duodenum. (4) Over 20 years old (5) ECOG PS of 0 or 1 (6) No previous history of surgical resection for pancreatic cancer (7) No previous history of radiation therapy for abdominal malignancy (8) Adequate organ functions (9) Written informed consent
Exclusion criteria
Exclusion criteria: (1) A metallic stent has been inserted in the bile duct and duodenum. (2) Peritoneal dissemination has been confirmed by peritoneal cytology within 4 weeks prior to enrollment. (3) Cases with severe complication such as heart disease, renal disease, and hepatic disease (4) An infectious disease (excluding viral hepatitis) that requires systemic treatment (5) Other active malignancy at the start of our study (6) Patients requiring systemic steroids medication or other immunosuppressants (7) Patients who can' t receive neither iodic drug nor gadolinium because of drug allergy (8) Cases with severe psychological disorder (9) Other cases that were judged to be inappropriate for conducting this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year locoregional control | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Progression-free survival, Distant metastasis-free survival, the acute and late toxicities, the rate of conversion surgery, Disease control rate. Tumor marker kinetics | — |
Countries
Japan
Contacts
Public ContactRei Umezawa
Tohoku University Hospital Department of Radiation Oncology
Outcome results
None listed